Acumen reports Q1 net loss of $14.9M; Phase 2 sabirnetug trial initiated

Acumen Pharmaceuticals, Inc.

2024-Q1 EPS reported -$0.25

Net loss of $14.9M for Q1 2024 vs. $11.3M in Q1 2023; R&D expenses rose to $12.4M.
Cash, equivalents and marketable securities totaled $296.6M as of March 31, 2024; expected to fund operations into H1 2027.
First patient dosed in ALTITUDE-AD Phase 2 study of sabirnetug for early Alzheimer's in May 2024.
Phase 1 subcutaneous dosing study of sabirnetug expected to start mid-2024; Lonza collaboration for manufacturing announced.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Acumen Pharmaceuticals, Inc. reported first quarter of 2024 results: net income $14.9 million.

Period: first quarter of 2024
Net income: $14.9 million
Result: reported results

Exact text from the filing

Acumen Pharmaceuticals, Inc. (the “ Company ”) reported financial results and business highlights for the quarter ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Acumen Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001576885-24-000061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.